Skip to Content
Merck
CN
  • Preemptive thoracic drainage to eradicate postoperative pulmonary complications after living donor liver transplantation.

Preemptive thoracic drainage to eradicate postoperative pulmonary complications after living donor liver transplantation.

Journal of the American College of Surgeons (2014-12-03)
Daisuke Imai, Toru Ikegami, Takeo Toshima, Tomoharu Yoshizumi, Yo-ichi Yamashita, Mizuki Ninomiya, Norifumi Harimoto, Shinji Itoh, Hideaki Uchiyama, Ken Shirabe, Yoshihiko Maehara
ABSTRACT

Thoracic fluid retention after living donor liver transplantation (LDLT) has various negative consequences, including atelectasis, pneumonia, and respiratory distress or failure. We analyzed the clinical impact of preemptive thoracic drainage in 177 patients undergoing adult-to-adult LDLT for chronic liver diseases at a single center. Recipients were divided into 2 time periods. The earlier cohort (n = 120) was analyzed for risk factors for postoperative atelectasis retrospectively; the later cohort (n = 57), with a risk factor for postoperative atelectasis, underwent preemptive thoracic drainage prospectively. The incidence of postoperative pulmonary complications was compared between these 2 cohorts. Independent risk factors for atelectasis in earlier cohort were body mass index ≥27 kg/m(2) (p < 0.001), performance status ≥3 (p = 0.003) and model for end-stage liver disease score ≥23 (p = 0.005). The rates of atelectasis (21.1% vs 42.5%, p = 0.005) and pneumonia (1.8% vs 10.0%, p = 0.049) were significantly lower in later than in earlier cohort. Moreover, the mean durations of ICU stay (3.6 ± 0.2 days vs 5.7 ± 0.6 days, p = 0.038) and postoperative oxygen support (5.1 ± 0.8 days vs 7.1 ± 0.5 days, p = 0.037) were significantly shorter in the later than in the earlier cohort. There were no significant differences in the incidence of adverse events associated with thoracic drainages between these 2 cohorts. Preemptive thoracic drainage for transplant recipients at high risk of postoperative atelectasis could decrease morbidities after LDLT.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
FK-506 monohydrate, ≥98% (HPLC)
USP
Tacrolimus, United States Pharmacopeia (USP) Reference Standard
USP
Mycophenolate mofetil, United States Pharmacopeia (USP) Reference Standard
Mycophenolate mofetil, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
(±)-CPP, solid
Mycophenolate mofetil for peak identification, European Pharmacopoeia (EP) Reference Standard